Zacks Research Predicts Sanofi’s Q2 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Equities research analysts at Zacks Research dropped their Q2 2026 earnings per share (EPS) estimates for Sanofi in a research note issued on Thursday, December 11th. Zacks Research analyst Team now anticipates that the company will post earnings of $1.09 per share for the quarter, down from their prior estimate of $1.10. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q1 2027 earnings at $1.11 EPS.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 24th. The company reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $1.31. The firm had revenue of $15.46 billion during the quarter, compared to analysts’ expectations of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business’s revenue was down 7.5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.25 EPS.

A number of other equities analysts have also recently commented on SNY. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $56.00 to $58.00 in a report on Monday, September 8th. Guggenheim lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $62.67.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $47.44 on Monday. The stock has a market cap of $116.49 billion, a P/E ratio of 11.11, a P/E/G ratio of 1.30 and a beta of 0.44. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The stock has a 50 day moving average of $49.79 and a two-hundred day moving average of $48.98. The company has a current ratio of 1.06, a quick ratio of 0.30 and a debt-to-equity ratio of 0.16.

Institutional Investors Weigh In On Sanofi

A number of institutional investors have recently added to or reduced their stakes in the business. Voya Investment Management LLC increased its stake in Sanofi by 11.6% in the first quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock valued at $11,460,000 after purchasing an additional 21,540 shares during the last quarter. Callodine Capital Management LP grew its holdings in Sanofi by 26.9% in the 2nd quarter. Callodine Capital Management LP now owns 515,209 shares of the company’s stock valued at $24,890,000 after buying an additional 109,240 shares during the period. Ascent Group LLC acquired a new position in shares of Sanofi during the 1st quarter valued at about $426,000. 1248 Management LLC purchased a new position in shares of Sanofi during the 1st quarter worth about $518,000. Finally, Equity Investment Corp boosted its position in shares of Sanofi by 2.5% in the second quarter. Equity Investment Corp now owns 2,512,435 shares of the company’s stock worth $121,376,000 after acquiring an additional 62,109 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.